“Glucose, urea, and creatinine laboratory tests in people starting antiretroviral therapy with dolutegravir or efavirenz: a cohort study in Belo Horizonte, Brazil”, RSD, vol. 11, no. 5, p. e43711528541, Apr. 2022, doi: 10.33448/rsd-v11i5.28541.